Pharmacologic intervention and medical support of the HIV-infected child have to be clearly focused on improving duality of life and decreasing the rate of disease progression. The optimal timing and agents will be defined as we find answers to crucial questions such as: How early to intervene? Should we have a single or multiple agent approach? Answers to these questions are critically needed. Well-designed and conducted clinical trials will shed light and needed data to answer these questions and will allow us to redefine recommendations for the near future.
|Original language||English (US)|
|Number of pages||26|
|Journal||Immunology and Allergy Clinics of North America|
|State||Published - Jun 8 1995|
ASJC Scopus subject areas
- Immunology and Allergy